M. Badillo

发表

A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma

Michael L. Wang, H. Lee, J. Romaguera, 2019, British journal of haematology.

Phase I/II study of high dose pomalidomide with G‐CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma

Michael L. Wang, P. Jain, R. Orlowski, 2020, American journal of hematology.

Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma.

P. Jain, J. Khoury, C. Pinnix, 2019, Blood advances.

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Michael L. Wang, Y. Oki, K. Young, 2016, The Lancet. Oncology.

Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma

Michael L. Wang, Shouhao Zhou, Q. Cai, 2014, Oncotarget.

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

Michael L. Wang, Shaojun Zhang, Guangchun Han, 2019, Science Translational Medicine.

A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma

Michael L. Wang, H. Lee, J. Romaguera, 2020, British journal of haematology.

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

C. Flowers, Linghua Wang, Xuelin Huang, 2022, The Lancet. Oncology.

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma

Michael L. Wang, C. Flowers, Linghua Wang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2018, British journal of haematology.

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, American journal of hematology.

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2019, Blood.

Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

Michael L. Wang, P. Jain, R. Kanagal-Shamanna, 2018, British journal of haematology.

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

W. Wang, V. Jiang, R. Lin, 2023, The Journal of clinical investigation.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

Michael L. Wang, J. Shah, M. Wang, 2013, Leukemia.

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Michael L. Wang, C. Flowers, Shaojun Zhang, 2021, Nature Communications.

Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

Michael L. Wang, C. Flowers, P. Jain, 2020, British journal of haematology.

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

Michael L. Wang, C. Flowers, Shaojun Zhang, 2021, American journal of hematology.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

P. Mclaughlin, F. Cabanillas, K. Young, 2012, The Lancet. Oncology.

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, Blood advances.

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

Michael L. Wang, R. Orlowski, Liang Zhang, 2014, Journal of Hematology & Oncology.

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Michael L. Wang, Shouhao Zhou, Sabah Kadri, 2017, Clinical Cancer Research.

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

M. Badillo, Gretchen A. McNally, L. Brophy, 2015, Journal of the advanced practitioner in oncology.

Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment

Michael L. Wang, Evita T. Sadimin, J. Schenkel, 2019, British journal of haematology.

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.

Michael L. Wang, Y. Oki, K. Nomie, 2017, The oncologist.

Sexism, Personality, Psychopathology, and Leisure Activities in Colombian Adolescents: Differences as a Function of the Level of Development of the City of Residence

Maite Garaigordobil, M. Badillo, 2011 .

Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial

Michael L. Wang, F. Turturro, Shaoying Li, 2016 .

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Michael L. Wang, F. Turturro, L. Kwak, 2014 .

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Michael L. Wang, H. Lee, A. Zloza, 2017 .

IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO

F. Turturro, S. Huang, Suping Zhou, 2017 .

Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial

Michael L. Wang, C. Flowers, P. Jain, 2021, Blood.

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Michael L. Wang, Shouhao Zhou, Sabah Kadri, 2017, Clinical Cancer Research.

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Michael L. Wang, Linghua Wang, K. Patel, 2019, Blood.